MedEsthetics magazines offers business education and in-depth coverage of the latest noninvasive cosmetic procedures for physicians and practice managers working in the medical aesthetics industry.
Issue link: https://medesthetics.epubxp.com/i/535392
60 JULY/AUGUST 2015 | Med Esthetics ASAPS AND ASERF NAME NEW PRESIDENTS James C. Grotting, MD, is the new president of the American Society for Aesthetic Plastic Surgery (ASAPS). The results of the election were announced during The Aesthetic Meeting in Montreal on May 14-18. Dr. Grotting is currently in private practice in Birmingham, Alabama. He is the past- president of the Southeastern Society of Plastic Surgeons, a clinical professor of plastic surgery at the University of Alabama at Birmingham, and a director and oral examiner for the American Board of Plastic Surgery. "While it has been an honor and privilege to have served as ASAPS President for the past year, I can think of no better colleague to hand the reins to than Dr. Grotting," said Michael Edwards, MD, immediate past president of ASAPS. "A noted lecturer, teacher, clinician and true thought leader in our specialty, he will use his educational experience and fair, balanced judgment to lead The Aesthetic Society in shaping the aesthetic landscape." The ASAPS research and education arm, the Aesthetic Surgery Education and Research Foundation (ASERF) also elected a new president: Neal R. Reisman, MD. Dr. Reisman pioneered split-muscle natural breast augmentation and short-scar mini-facelifts, and served as the chief of surgery at numerous hospitals in the Houston area. He obtained his law degree from South Texas College of Law and has lectured and written extensively on cosmetic surgery, ethics and the business of plastic surgery, as well as medicolegal issues relating to plastic surgery. "As my successor, Dr. Reisman is a proven leader with vast experience which will serve well to advance ASERF's mission, shaping the aesthetic surgery landscape through evidence-based research fi ndings that benefi t patients, physicians and the entire fi eld of medicine," said Al Aly, MD, immediate past president of ASERF. KYBELLA INJECTABLE APPROVED FOR SUBMENTAL FAT KYBELLA injection (deoxycholic acid, KYTHERA Biopharmaceutcials), previously known as ATX-101, has been FDA approved for contouring moderate to severe convexity or fullness associated with submental fat in adults. KYBELLA is a nonhuman and non- animal formulation of deoxycholic acid that aids in the breakdown and absorption of dietary fat. When injected into subcutaneous fat, the drug destroys fat cells. The approval was based on the results of over 20 clinical studies involving more than 2,600 patients. According to KYTHERA, patients can receive up to 50 injections in a single treatment, with up to six single treatments administered no less than one month apart. Treatment sessions typically take 15 to 20 minutes, and many patients experience visible results after two to four treatments. Once the aesthetic response is achieved, re-treatment is not expected. The most common adverse reactions in clinical trial subjects were associated with the injection site and included swelling, bruising, pain, numbness, erythema and formation of small areas of fi rmness around the treatment area. The percentage of adverse reactions reported as mild were 81%, moderate 17.4% and severe 1.6%. SYNCHRO REPLA:Y CLEARED FOR HIGHER FLUENCE AND LARGER SPOT SIZE DEKA Medical, developer and distributor of light-based aesthetics systems, has received additional Food and Drug Administration (FDA) clearance for its Synchro REPLA:Y family of three laser platforms, allowing for a maximum power of 180W and a 24mm spot size, the largest currently available. Each Synchro REPLA:Y platform—the Excellium 3.4, the Excellium HP and the Premium 1.4.2—is designed to treat a range of indications, including hair removal, pseudo folliculitis barbae, benign pigmented lesions, wrinkles and photocoagulation of vascular lesions. Their new 180W setting now allows for maximum fl uence combined with the largest 24mm spot size, enabling physicians to offer effi cient high-speed treatments with each multi-wavelength work station. For more information, visit dekamedinc.com. VENUS VIVA FDA APPROVED FOR ABLATION AND RESURFACING Venus Viva (Venus Concept) is now FDA approved for facial skin ablation and resurfacing. The minimally invasive NanoFractional Radio Frequency device delivers treatment via SmartScan technology. Providers can manually control ablation and coagulation for enhanced effi ciency and patient comfort. "Our research showed great effi cacy on a variety of different clinical indications including excellent results on facial wrinkles with no downtime and a very high level of patient comfort and satisfaction," said Neil Sadick, MD, a board certifi ed dermatologist from New York who participated in the clinical trials. AAD OFFERS INTERNATIONAL TRAVEL GRANTS Dermatologists and dermatology residents may apply for two international travel grants being offered by the NEWS & EVENTS James C. Grotting, MD Neal R. Reisman, MD